Abstract: Objective To observe the treatment effect of Anluohuaxian pills combined ursodeoxycholic acid capsules on primary biliary cirrhosis patients. Methods Total of 64 patients with primary biliary cirrhosis were randomly divided into treatment group (32 cases) and control group (32 cases). The control group were
given diammonium glycyrrhizinate enteric-coated capsules and ursodeoxycholic acid capsules (UDCA), and the treatment group were treated with Anluohuaxian pills on the basis of the control group. After a treatment course of three months, the changes of clinical symptoms, physical signs, liver function, liver fibrosis, and liver and spleen imaging were observed and compared with before treatment. Results No obvious adverse reaction occurred in the two groups during the treatment. The efficiency of the treatment group (90.6%) was significantly higher than the control group (68.8%) (P = 0.024). The level of serum ALT, AST, ALP, GGT of the treatment group decreased significantly ( a P = 0.082,  * P = 0.0008， # P = 0.037) compared with the control group. After treatment, the liver and spleen imaging changes of the treatment group significantly improved in liver photoelectric intensive compared with the control group ( a P ＜ 0.021). Conclusions Anluohuaxian pills combined with ursodeoxycholic acid capsules have obvious curative treatment effects and less side effects on
primary biliary cirrhosis and can improve fibrosis and clinical indexes of liver imaging.